Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Cyst Fibros. 2017 Nov;16(6):695-701. doi: 10.1016/j.jcf.2017.02.006. Epub 2017 Apr 6.

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.

Author information

1
Cork Adult Cystic Fibrosis Centre, University College Cork, Cork University Hospital, Cork, Ireland. Electronic address: b.plant@ucc.ie.
2
Belfast Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK.
3
Cork Adult Cystic Fibrosis Centre, University College Cork, Cork University Hospital, Cork, Ireland.
4
Cystic Fibrosis Unit, Beaumont Hospital, Dublin, Ireland.
5
Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK.
6
Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester, Manchester, UK.
7
Department of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland.
8
Regional Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds, UK.
9
All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Cardiff, UK.
10
Department of Respiratory Medicine, Royal Brompton Hospital, London, UK.

Abstract

BACKGROUND:

Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).

METHODS:

Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.

RESULTS:

Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).

CONCLUSIONS:

In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.

KEYWORDS:

Aztreonam; Cystic fibrosis; Evaluation tool; Forced expiratory volume; Intravenous antibiotics

PMID:
28392014
DOI:
10.1016/j.jcf.2017.02.006
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center